Revolution Medicines (NASDAQ:RVMD) COO Sells $372,346.54 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 4,847 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total transaction of $372,346.54. Following the completion of the transaction, the chief operating officer directly owned 141,053 shares in the company, valued at approximately $10,835,691.46. This represents a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD traded down $0.78 during trading on Thursday, reaching $75.96. 2,749,530 shares of the stock were exchanged, compared to its average volume of 2,009,908. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $81.49. The stock has a 50-day moving average price of $65.55 and a 200-day moving average price of $48.76. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16. The firm has a market cap of $14.68 billion, a PE ratio of -14.69 and a beta of 0.96.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same period in the prior year, the company posted ($0.94) earnings per share. Research analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in RVMD. GAMMA Investing LLC boosted its position in shares of Revolution Medicines by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after acquiring an additional 260 shares in the last quarter. CWM LLC raised its position in Revolution Medicines by 171.3% during the second quarter. CWM LLC now owns 917 shares of the company’s stock valued at $34,000 after purchasing an additional 579 shares in the last quarter. Banque Transatlantique SA bought a new stake in Revolution Medicines during the first quarter worth $42,000. Quarry LP acquired a new stake in shares of Revolution Medicines in the 1st quarter valued at $50,000. Finally, Twin Tree Management LP acquired a new stake in shares of Revolution Medicines in the 1st quarter valued at $58,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group lifted their target price on Revolution Medicines from $65.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Wolfe Research started coverage on shares of Revolution Medicines in a research report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 target price on the stock. Wells Fargo & Company raised their target price on shares of Revolution Medicines from $67.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. HC Wainwright boosted their price target on Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Wedbush increased their price target on Revolution Medicines from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $78.50.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.